Dr. Reddy's Laboratories Limited (RDY)

NYSE: RDY · Pharmaceutical Preparations · Hyderabad, IN · filing with the SEC since 2001

Full chart Alerts Compare

Grade6.5

◀ Past 7.5● Present 6.9▶ Future 5.1

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Dr. Reddy's Laboratories Limited

Nine metrics read from its own filings, by tense

Headline grade

6.5/10

◀ Past7.530% of the headline

● Present6.940% of the headline

▶ Future5.130% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

7.5/1030% of the headline grade · 3 of 3 filed

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 33% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Dr. Reddy's Laboratories Limited's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

7.3/10

What has it actually done, year after year?

+8.6% a year over 10 filed years; profitable in 10 of 10.

weight 45% of this tense · 73rd percentile among 323 sector filers · read for its customers

From the record

Dr. Reddy's Laboratories Limited's 10 filed years say what it did: revenue went from INR 155 billion in fiscal 2016 to INR 326 billion in fiscal 2025, up 8.6% a year; it rose in 8 of 9 years; the deepest fall was 9% from fiscal 2016 to fiscal 2017; net income was positive in 10 of 10 of those years (its annual reports).

What it rests on

revenue growth over the filed span8.6%bottom 42% of its family
the share of years revenue rosetop 18% of its family
the share of filed years with a profittop 3% of its family
the deepest fall from a revenue peak9.0%top 28% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

as filed

6.7/10

How has it treated the people who own it?

Share count grew 0.1% a year. 12% of cash flow returned. Insiders: 0 sales, 0 purchases.

weight 22% of this tense · 67th percentile among 80 sector filers · read for its shareholders

From the record

Over the 3 fiscal years to 2025-03-31, Dr. Reddy's Laboratories Limited's diluted share count grew about 0.1% a year, and dividends and buybacks returned about 12% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

What it rests on

the share count over the yearstop 12% of its family
cash returned against operating cash flowbottom 46% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

● Present

What are they doing right now?

6.9/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

7.6/10

Is it financially healthy right now?

ROE 17%: 17¢ of profit per shareholder dollar. Leverage 32%: owes 32¢ per asset dollar.

weight 45% of this tense · 76th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-03-31, Dr. Reddy's Laboratories Limited earned about 17 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 39 cents per dollar of everything the company owns. Leverage: it owed about 32 cents per dollar of assets, and net share issuance: its share count grew 0.1% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 48% of its family
return on equitytop 8% of its family
gross profit against assetstop 31% of its family
the share count against the year beforetop 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

7.3/10

How strong is its position in its industry?

top 27% of 315 in its family; net margin 17.6%.

weight 33% of this tense · 73rd percentile among 315 sector filers · read for its customers

From the record

Dr. Reddy's Laboratories Limited's standing among 315 graded names in its industry family: revenue of INR 326 billion in fiscal 2025 is not ranked by size, since the family reports in another currency; a net margin of 17.6% ranks in the top 12%; revenue growth of 14.9% a year over the last 3 filed years ranks in the top 42% (its annual reports).

What it rests on

net margin17.6%top 12% of its family
three-year revenue growth14.9%top 42% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-20 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-20 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: family median, 371 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Dr. Reddy's Laboratories Limited's leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-20 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.1/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

3.5/10

How much room does it have to grow?

bottom 35% of 273 in its family for room to expand.

weight 45% of this tense · 35th percentile among 273 sector filers · read for itself

From the record

Dr. Reddy's Laboratories Limited's room to grow, from the newest filed statements (fiscal 2025): cash of INR 15 billion against debt of INR 8.7 billion leaves 1.2% of its assets as net cash, bottom 15% of its family; cash from operations less capital spending is 5.8% of revenue (top 25%); a gross margin of 58.5% (bottom 36%); research spending of 8.4% of revenue (bottom 13%) (its annual report).

What it rests on

cash less debt against assets1.2%bottom 15% of its family
cash from operations less capital spending against revenue5.8%top 25% of its family
gross margin58.5%bottom 36% of its family
research spending against revenue8.4%bottom 13% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

7.2/10

What could actually drive growth from here?

top 28% of 306 in its family for growth drivers.

weight 33% of this tense · 72nd percentile among 306 sector filers · read for its customers

From the record

Dr. Reddy's Laboratories Limited's growth drivers, from the filed years to fiscal 2025: revenue grew 14.9% a year over the last three filed years against 8.6% over all 10, speeding up (top 22% of its family); the newest year grew 16.6% (top 40%); research spending grew 16.1% a year (top 29%); capital spending grew 23.3% a year (top 23%) (its annual reports). Dr. Reddy's Laboratories Limited tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+6.3 points a yeartop 22% of its family
the newest year's revenue growth16.6%top 40% of its family
three-year growth of research spending16.1%top 29% of its family
three-year growth of capital spending23.3%top 23% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

5.3/10

Did its newest year beat what its own record pointed to?

top 47% of 233 in its family for expectations against reality.

weight 22% of this tense · 53rd percentile among 233 sector filers · read for its shareholders

From the record

Dr. Reddy's Laboratories Limited's newest year against its own record: revenue of INR 326 billion in fiscal 2025 came in 2.2% above the INR 319 billion its prior three years' pace pointed to (top 41% of its family); net income of INR 57 billion against a prior three-year average of INR 41 billion (top 38%); a net margin of 17.6% against 16.4% before (bottom 36%) (its annual reports).

What it rests on

revenue against the prior three years' pace2.2%top 41% of its family
net income against the prior three years' average+38%top 38% of its family
net margin against its prior average+1.2 pointsbottom 36% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton RDY · research, not advice